Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Longhua Sun

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
The Lancet. Respiratory Medicine|June 23, 2025
Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trialYuankai Shi, Lin Wu, Yinghua Ji, et al.
Insects|December 22, 2023
Demonstration of RNAi Yeast Insecticide Activity in Semi-Field Larvicide and Attractive Targeted Sugar Bait Trials Conducted on <i>Aedes</i> and <i>Culex</i> MosquitoesAkilah T M Stewart, Keshava Mysore, Teresia M Njoroge, et al.
BMJ (Clinical Research Ed.)|June 5, 2025
Sacituzumab tirumotecan versus docetaxel for previously treated <i>EGFR</i>-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trialWenfeng Fang, Xingya Li, Qiming Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 10, 2024
Efficacy and Safety of KRASG12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal StudyQing Zhou, Xiangjiao Meng, Longhua Sun, et al.
European Journal of Cancer (Oxford, England : 1990)|October 2, 2024
Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: First-in-human phase I studyQing Zhou, Nong Yang, Mingfang Zhao, et al.
The Lancet. Oncology|February 28, 2025
Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm studyZiming Li, Yan Wang, Yuping Sun, et al.
The New England Journal of Medicine|June 2, 2025
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based ChemotherapyGiannis Mountzios, Longhua Sun, Byoung Chul Cho, et al.
Nature Medicine|April 10, 2025
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trialsShen Zhao, Ying Cheng, Qiming Wang, et al.
Lancet (London, England)|January 16, 2026
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trialShun Lu, Jie Wang, Nong Yang, et al.
Cancer Cell|June 18, 2026
Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancerJun Liao, Wenxiu Yao, Yan Yu, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
The Lancet. Respiratory Medicine|June 23, 2025
Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trialYuankai Shi, Lin Wu, Yinghua Ji, et al.
Insects|December 22, 2023
Demonstration of RNAi Yeast Insecticide Activity in Semi-Field Larvicide and Attractive Targeted Sugar Bait Trials Conducted on <i>Aedes</i> and <i>Culex</i> MosquitoesAkilah T M Stewart, Keshava Mysore, Teresia M Njoroge, et al.
BMJ (Clinical Research Ed.)|June 5, 2025
Sacituzumab tirumotecan versus docetaxel for previously treated <i>EGFR</i>-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trialWenfeng Fang, Xingya Li, Qiming Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 10, 2024
Efficacy and Safety of KRASG12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal StudyQing Zhou, Xiangjiao Meng, Longhua Sun, et al.
European Journal of Cancer (Oxford, England : 1990)|October 2, 2024
Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: First-in-human phase I studyQing Zhou, Nong Yang, Mingfang Zhao, et al.
The Lancet. Oncology|February 28, 2025
Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm studyZiming Li, Yan Wang, Yuping Sun, et al.
The New England Journal of Medicine|June 2, 2025
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based ChemotherapyGiannis Mountzios, Longhua Sun, Byoung Chul Cho, et al.
Nature Medicine|April 10, 2025
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trialsShen Zhao, Ying Cheng, Qiming Wang, et al.
Lancet (London, England)|January 16, 2026
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trialShun Lu, Jie Wang, Nong Yang, et al.
Cancer Cell|June 18, 2026
Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancerJun Liao, Wenxiu Yao, Yan Yu, et al.
Pageof 9